Sanofi has invested significantly in advancing biotechnologies through both research and acquisitions. The pharma giant has recently penned a $1.8B research deal for 2 bispecific antibodies focused on autoimmune and immunology. In partnership with
Regeneron, they also secured their 7th FDA approval for
Dupixent, a drug designed to treat a hives condition. Sanofi further expanded its portfolio by paying $125M upfront for two immunology drugs from Earendil, a startup biotech. Despite a stumble in the Phase II trials of its Asthma drug originally developed by
Kymab, the company continues to pour resources into the development of AI-discovered bispecifics and diverse partnerships to supplement its pipeline. Notably, it has also committed to the promotion of healthcare access and sustainability, and signed up celebrity Chrissy Teigen for its diabetes screening campaign.
Sanofi's efforts also include a substantial China investment which envisages an insulin 'manufacturing base' in Beijing.
Sanofi News Analytics from Wed, 10 Jul 2024 15:23:29 GMT to Sat, 19 Apr 2025 15:20:09 GMT -
Rating 5
- Innovation 4
- Information 7
- Rumor -3
